In order to assess the risk of hepatitis B reactivation in people living with HIV and undergoing injection therapy, we propose to carry out a descriptive analysis of the evolution of hepatitis B markers in this population.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Risk of HBV reactivation under injectable HIV ART
Timeframe: From start of injectable HIV treatment to hepatitis B reactivation, assessed up to 24 months